{
  "id": 15323236,
  "title": "Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?",
  "url": "https://urgent.news/2026/10/18/cathie-wood-keeps-buying-beam-therapeutics-on-the-dip-should-you",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-18T01:00:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/17/cathie-wood-keeps-buying-beam-therapeutics-on-the/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Cathie Wood, CEO of Ark Investment Management, has recently added $2.8 million to her Beam Therapeutics (BEAM) holdings through Ark Genomic Revolution fund. Beam specializes in a precise gene editing technique called base editing, which allows for targeted modifications to the genetic code without causing harmful DNA breaks. This technology sets Beam apart from traditional CRISPR-Cas9 methods, which carry risks of unintended chromosomal rearrangements. Beam's therapies are in early-stage trials, focusing on high-value diseases such as sickle cell disease (SCD) and alpha-1 antitrypsin deficiency (AATD). The company's lead therapy, ristoglogene autogetemcel, is an investigational ex vivo cell therapy that modifies a patient's own hematopoietic stem cells to produce fetal hemoglobin and suppress sickling. Beam maintains a relatively strong balance sheet, with $1.15 billion in cash as of Q2, supporting operations through mid-2029. Although the company reported a $2.09 loss per share in its first six months, revenue grew by 50.5% year-over-year. As Beam's programs progress through phase 1/2 clinical trials, the next 12 to 18 months will provide crucial regulatory and clinical data readouts. A positive outcome could significantly boost the stock price, making Beam Therapeutics an attractive investment for those willing to manage potential volatility and risk.",
  "summary": "The gene-editing biotech stock is down more than 12% this year.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?",
        "url": "https://urgent.news/2026/10/18/cathie-wood-keeps-buying-beam-therapeutics-on-the-dip-should-you-15330996",
        "published": "2026-10-18T01:20:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}